NASDAQ:AMGNAmgen Stock Price, Forecast & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMGN stock has increased by 30.0% and is now trading at $258.24. View which stocks have been most impacted by Coronavirus.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 11 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Amgen.

Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings results on Thursday, April, 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.70 by $0.47. The medical research company had revenue of $6.16 billion for the quarter, compared to analysts' expectations of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. The business's quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.56 EPS. View Amgen's earnings history.

Amgen declared a quarterly dividend on Wednesday, March 4th. Investors of record on Monday, May 18th will be given a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 annualized dividend and a yield of 2.48%. The ex-dividend date of this dividend is Friday, May 15th. View Amgen's dividend history.

Amgen updated its FY20 earnings guidance on Thursday, April, 30th. The company provided earnings per share guidance of $14.85-15.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.34. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.21 billion.

28 equities research analysts have issued 1-year price targets for Amgen's stock. Their forecasts range from $185.00 to $291.00. On average, they expect Amgen's share price to reach $246.08 in the next twelve months. This suggests that the stock has a possible downside of 4.7%. View analysts' price targets for Amgen.

Press coverage about AMGN stock has been trending negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amgen earned a news impact score of -2.1 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Amgen.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD) and AbbVie (ABBV).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Birch Capital Management LLC (0.00%), Fulton Bank N. A. (0.00%), Gantzert Investment Co. LLC ADV (0.00%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%), Thomasville National Bank (0.00%) and M&R Capital Management Inc. (0.00%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Nelson Van Denburg & Campbell Wealth Management Group LLC, M&R Capital Management Inc., and Gantzert Investment Co. LLC ADV. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Ellenbecker Investment Group, Fulton Bank N. A., and Birch Capital Management LLC. View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $258.24.

Amgen has a market capitalization of $151.91 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]